Effect of Nadolol in Treatment of Hypertension
Authors:
- Ladislav VolicerLVLadislav Volicer
- Chang‐Seng LiangCLChang‐Seng Liang
- Irene GavrasIGIrene Gavras
- Dean L. GriffithDGDean L. Griffith
- 3 February 1979
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 19 (2-3) , 137-147
Abstract
Nadolol, a new beta-adrenergic blocking agent, was administered orally in gradually increasing single daily doses to 13 hospitalized patients with essential hypertension. Maximal doses ranged from 200 to 480 mg/day. Blood pressure was reduced in nine patients and heart rate was decreased in 11 patients. The decrease in blood pressure was either partial or temporary in five of the nine patients who responded. Concomitant administration of the diuretic chlorthalidone decreased blood pressure in a previously unresponsive patient. Nadolol effectively inhibited isoproterenol-induced tachycardia and decreased cardiac output by 18 per cent. Plasma renin activity and plasma aldosterone concentration were not changed significantly by the treatment. Body weight was not altered significantly. Blood pressure response was independent of the pretreatment renin levels or the change in renin induced by nadolol; it was also independent of the changes in cardiac output and heart rate but was more pronounced in patients with milder baseline hypertension. The decline in serum concentration of nadolol was consistent with the drug's reported half-life of 12.2 hours. The results indicate that single daily doses of nadolol alone can reduce blood pressure significantly with minimal cardiodepressant effects and no important side effects. The effectiveness of nadolol may be enhanced by the addition of a diuretic.Keywords
This publication has 23 references indexed in Scilit:
- Fluorometric Determination of Nadolol in Human Serum and UrineJournal of Pharmaceutical Sciences, 1977
- Mechanism of action of β-blockers in hypertensionBiochemical Pharmacology, 1977
- Acute and long-term studies of the mechanisms of action of beta-blocking drugs in lowering blood pressureThe American Journal of Medicine, 1976
- Controlled treatment of primary hypertension with propranolol and spironolactoneThe American Journal of Cardiology, 1976
- Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertensionEuropean Journal of Clinical Pharmacology, 1976
- Pharmacology of nadolol (SQ 11725), a β-adrenergic antagonist lacking direct myocardial depressionEuropean Journal of Pharmacology, 1975
- Comparative studies on central factors contributing to the hypotensive action of propranolol, alprenolol, and their enantiomersCardiovascular Research, 1974
- β-Blockers and Plasma Renin Activity in HypertensionBMJ, 1974
- Steady-state plasma concentrations of alprenolol in manEuropean Journal of Clinical Pharmacology, 1974
- Cardiovascular responses to carotid and vertebral artery infusions of propranololCardiovascular Research, 1971